Investors

We are Zogenix.

We are a premier specialty pharmaceutical company providing innovative therapeutics to patients. Our focus is on improving patient outcomes by developing and responsibly commercializing differentiated products through unique drug delivery systems for CNS disorders and pain.

We broadly leverage our drug delivery technologies with partners for the benefit of physicians and patients in other therapeutic areas. We are building an organization that makes a difference in t... More >>

Title   Zogenix January 2013 Investor Presentation

ZGNX (Common Stock) Exchange NASDAQ (US Dollar) Price $1.47 Change (%)   0.07 (5.00%) Volume 282,684 Data as of 06/17/13 4:00 p.m. ET Minimum 20 minute delay Refresh quote

Date Title   06/05/13 Zogenix Announces Initiatives to Reach Key Business Milestones Cost Control Initiatives Extend Cash Runway SAN DIEGO, June 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today initiatives to extend its cash runway to reach key business milestones that may occur over the remainder of the year. These milestones include the Company's efforts to gain U.S. Food and Drug Administration (FDA) approval for its New Dru...  05/20/13 Zogenix and Battelle to Present Positive, New Data Demonstrating Value of Needle-Free Injection for Biologics DosePro Studies to be Presented at 2013 AAPS National Biotechnology Conference SAN DIEGO and COLUMBUS, Ohio, May 20, 2013 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle Memorial Institute today announced new data supporting the value of the DosePro® needle-free injection technology in the delivery of biologics. The positive, new data will be presented in four poster presentations, including two posters co-authored by MedImmune, LLC, the worldwide biologics research...  05/09/13 Zogenix Reports First Quarter 2013 Financial Results Provides Update on Zohydro ER Conference Call and Webcast Today, May 9, at 4:30 p.m. ET SUMAVEL® DosePro® (sumatriptan injection) First Quarter 2013 Highlights Net product revenue of $7.0 million, reflecting a $1.2 million net adjustment to future product return reserve Generated approximately 20,000 total prescriptions Maintained positive quarterly refill rate at 41%* Recent Highlights and Milestones Reported positive top-line results from extend...  05/03/13 Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results Conference Call Scheduled for May 9, 2013 at 4:30 pm ET SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these finan...

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.